Related Experiment Videos
[Tiagabine in drug-resistant epilepsy in children: preliminary study]
J Wendorff1, M Popielarczyk, M Zubiel
1Klinika Neurologii Instytutu C.Z.M.P.
Insights
Tiagabine effectively treated drug-resistant epilepsy in children under 12. This study found tiagabine (TGB) safe and beneficial for pediatric epilepsy patients, reducing seizure frequency.
Area of Science:
- Pediatric Neurology
- Clinical Pharmacology
Background:
- Epilepsy affects children globally, with drug-resistant forms posing significant challenges.
- Exploring novel therapeutic options for pediatric epilepsy is crucial.
Observation:
- This study evaluated tiagabine (TGB) as an add-on therapy in four children under 12 with drug-resistant epilepsy.
- Patients received TGB alongside carbamazepine (CBZ) or valproate (VPA).
Findings:
- One patient achieved complete seizure remission.
- Three patients experienced a significant reduction in daily seizure frequency (2-4 seizures/day).
- No adverse events necessitated treatment discontinuation.
Implications:
- Tiagabine demonstrates potential as a safe and effective treatment for refractory epilepsy in pediatric populations.
- Further research is warranted to confirm these preliminary findings in larger cohorts.
Unlabelled:
The aim of the study was the presentation of our preliminary experiences and the data concerning the efficacy and safety of tiagabine in patients below the 12-th year of life. 4 cases of drug--resistant epilepsy--with partial complex attacks in 3 and simple in 1 (frontal epilepsy from supplementary motor area) with multiple seizures in the day were the subject of the study. Tiagabine add-one therapy to CBZ or to VPA was used. Initial period--the dose titration lasted 4 weeks. The stable dosis period amounted to 5 months. The effective dosis of tiagabine was 1 mg/kg/day. In 1 case the seizures completely disappeared and in 3 the frequency decreased to 2-4 times in comparison to frequency per day before the treatment. There were not any side-effects reported which would be the cause of the drug discontinuation.
In Conclusion:
Tiagabine appeared to be an effective and safe drug in resistant epilepsy in children below 12 years of age.